Acerus Pharms Drug Patent Portfolio
Acerus Pharms owns 1 orange book drug protected by 5 US patents Given below is the list of Acerus Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11419914 | Safe desmopressin administration | 15 Jun, 2030 | Active |
| US9539302 | Safe desmopressin administration | 15 Jun, 2030 | Active |
| US7799761 | Pharmaceutical compositions including low dosages of desmopressin | 26 Sep, 2024 | Expired |
| US7405203 | Pharmaceutical compositions including low dosages of desmopressin | 06 May, 2023 | Expired |
| US7579321 | Pharmaceutical compositions including low dosages of desmopressin | 06 May, 2023 | Expired |
Latest Legal Activities on Acerus Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Acerus Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Jul, 2024 | US9539302 |
|
Recordation of Patent Grant Mailed
Critical
| 23 Aug, 2022 | US11419914 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 23 Aug, 2022 | US11419914 |
|
Email Notification
Critical
| 04 Aug, 2022 | US11419914 |
|
Issue Notification Mailed
Critical
| 03 Aug, 2022 | US11419914 |
| Mailing Corrected Notice of Allowability | 15 Jul, 2022 | US11419914 |
|
Email Notification
Critical
| 15 Jul, 2022 | US11419914 |
| Corrected Notice of Allowability | 12 Jul, 2022 | US11419914 |
|
Pubs Case Remand to TC
Critical
| 11 Jul, 2022 | US11419914 |
| Dispatch to FDC | 06 Jul, 2022 | US11419914 |
|
Email Notification
Critical
| 05 Jul, 2022 | US11419914 |
| Mailing Corrected Notice of Allowability | 05 Jul, 2022 | US11419914 |
|
Mail Notice of Allowance
Critical
| 30 Jun, 2022 | US11419914 |
|
Email Notification
Critical
| 30 Jun, 2022 | US11419914 |
|
Issue Fee Payment Received
Critical
| 30 Jun, 2022 | US11419914 |
Acerus Pharms Drug Patents' Oppositions Filed in EPO
Acerus Pharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 12, 2018, by Ferring B.V.. This opposition was filed on patent number EP10790053A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17168865A | Aug, 2020 | Ferring B.V. | Revoked |
| EP09796558A | May, 2019 | Ferring B.V. | Patent maintained as amended |
| EP10790053A | Mar, 2018 | Ferring B.V. | Granted and Under Opposition |
Acerus Pharms's Family Patents
Acerus Pharms Drug List
Given below is the complete list of Acerus Pharms's drugs and the patents protecting them.
1. Noctiva
Noctiva is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11419914 | Safe desmopressin administration |
15 Jun, 2030
(5 years from now)
| Active |
| US9539302 | Safe desmopressin administration |
15 Jun, 2030
(5 years from now)
| Active |
| US7799761 | Pharmaceutical compositions including low dosages of desmopressin |
26 Sep, 2024
(a month ago)
| Expired |
| US7405203 | Pharmaceutical compositions including low dosages of desmopressin |
06 May, 2023
(1 year, 6 months ago)
| Expired |
| US7579321 | Pharmaceutical compositions including low dosages of desmopressin |
06 May, 2023
(1 year, 6 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Noctiva's drug page